Leukemia Outcomes at KFSYSCC

Between 2015-2019, the five-year survival rate for leukemia at KFSYSCC was 63.5%.

Basic Information and Leukemia Types out of 483 Leukemia Patients at KFSYSCC from 1990-2019

  
    


    
    
    


    
    
        
                
                Total
                1990-1994
                1995-1999
                2000-2004
                2005-2009
                2010-2014
                2015-2019
            

        
                n
                483
                8 (2%)
                38 (8%)
                124 (26%)
                95 (20%)
                121 (25%)
                97 (20%)
            

                Gender (%)
            

                Male
                293 (61%)
                4 (50%)
                21 (55%)
                81 (65%)
                56 (59%)
                74 (61%)
                57 (59%)
            

                Female
                190 (39%)
                4 (50%)
                17 (45%)
                43 (35%)
                39 (41%)
                47 (39%)
                40 (41%)
            

                Age
            

                Mean/Median
                50/52
                59/64
                49/55
                46/46
                48/48
                54/57
                52/54
            

                Range
                2-97
                31-81
                2-83
                2-89
                7-93
                3-97
                6-96
            

                Q1-Q3
                37-65
                44-72
                34-68
                31-64
                33-60
                43-69
                45-63
            

                Stage (%)
            

                CLL
                58 (12%)
                1 (13%)
                3 (8%)
                6 (5%)
                3 (3%)
                16 (13%)
                29 (30%)
            

                CML
                22 (5%)
                0 (0%)
                0 (0%)
                2 (2%)
                3 (3%)
                6 (5%)
                11 (11%)
            

                ALL
                54 (11%)
                0 (0%)
                0 (0%)
                8 (6%)
                12 (13%)
                18 (15%)
                16 (16%)
            

                AML
                207 (43%)
                2 (25%)
                16 (42%)
                49 (40%)
                55 (58%)
                58 (48%)
                27 (28%)
            

                Others
                142 (29%)
                5 (63%)
                19 (50%)
                59 (48%)
                22 (23%)
                23 (19%)
                14 (14%)
            

    



  

	Total	1990-1994	1995-1999	2000-2004	2005-2009	2010-2014	2015-2019
n	483	8 (2%)	38 (8%)	124 (26%)	95 (20%)	121 (25%)	97 (20%)
Gender (%)
Male	293 (61%)	4 (50%)	21 (55%)	81 (65%)	56 (59%)	74 (61%)	57 (59%)
Female	190 (39%)	4 (50%)	17 (45%)	43 (35%)	39 (41%)	47 (39%)	40 (41%)
Age
Mean/Median	50/52	59/64	49/55	46/46	48/48	54/57	52/54
Range	2-97	31-81	2-83	2-89	7-93	3-97	6-96
Q1-Q3	37-65	44-72	34-68	31-64	33-60	43-69	45-63
Stage (%)
CLL	58 (12%)	1 (13%)	3 (8%)	6 (5%)	3 (3%)	16 (13%)	29 (30%)
CML	22 (5%)	0 (0%)	0 (0%)	2 (2%)	3 (3%)	6 (5%)	11 (11%)
ALL	54 (11%)	0 (0%)	0 (0%)	8 (6%)	12 (13%)	18 (15%)	16 (16%)
AML	207 (43%)	2 (25%)	16 (42%)	49 (40%)	55 (58%)	58 (48%)	27 (28%)
Others	142 (29%)	5 (63%)	19 (50%)	59 (48%)	22 (23%)	23 (19%)	14 (14%)

Based on KFSYSCC's cancer registry from 1990 to 2019, there were 483 analytic leukemia cases, with 293 males (61%) and 190 females (39%). The average and median ages were 50 and 52 years old, respectively; the youngest patient was 2 years old, and the oldest was 97 years old; the interquartile range (Q1-Q3) was 37- 65. According to the WHO 2017 classification of hematological cancers, there were 58 cases of CLL (12%), 22 cases of CML (5%), 54 cases of ALL (11%), 207 cases of AML (43%), and 142 cases of other leukemia (29%). The table above presents the basic patient information and stage distribution, categorized by the year of diagnosis.

A graph showing a declining exponential curve with color shading from blue to red, labeled axes, and a color scale bar at the bottom indicating values from 0 to 10, possibly representing data trends or distributions.

Survival Curves for 483 Leukemia Patients (1990-2019), Stratified by Year of Diagnosis

From 1990 to 2019, the chart below illustrates the five-year observed survival rates for 483 leukemia patients at KFSYSCC, stratified by the year of diagnosis. The graph shows the five-year survival rate for leukemia cancer increased from 50% in 1990-1994 to 64% in 2015-2019, while the ten-year survival rate decreased from 38% in 1990-1994 to 29% in 2010-2014.

Treatment Methods and Stages for 97 Leukemia Patients at KFSYSCC (2015-2019)

  
    


    
    
    


    
    
        
            Treatment/Condition
            Total
            CLL
            CML
            ALL
            AML
            Other
        

            Total
            97
            29
            11
            16
            27
            14
        

            Surgical Treatment
            0 (0%)
            -
            -
            -
            -
            -
        

            Radiation Therapy
            1 (1%)
            0 (0%)
            0 (0%)
            0 (0%)
            1 (4%)
            0 (0%)
        

            Chemotherapy
            60 (62%)
            9 (31%)
            1 (9%)
            16 (100%)
            27 (100%)
            7 (50%)
        

            Targeted Therapy
            22 (23%)
            7 (24%)
            11 (100%)
            1 (6%)
            1 (4%)
            2 (14%)
        

            Hormone Therapy
            7 (7%)
            2 (7%)
            0 (0%)
            5 (31%)
            0 (0%)
            0 (0%)
        

            Immunotherapy
            0 (0%)
            -
            -
            -
            -
            -
        

            Palliative Care
            7 (7%)
            0 (0%)
            0 (0%)
            3 (19%)
            2 (7%)
            2 (14%)
        

            Bone Marrow/Stem Cell Transplant
            14 (14%)
            0 (0%)
            0 (0%)
            4 (25%)
            9 (33%)
            1 (7%)
        

            No Record of Initial Treatment Reported
            23 (24%)
            20 (69%)
            0 (0%)
            0 (0%)
            0 (0%)
            3 (21%)
        





  

Treatment/Condition	Total	CLL	CML	ALL	AML	Other
Total	97	29	11	16	27	14
Surgical Treatment	0 (0%)	-	-	-	-	-
Radiation Therapy	1 (1%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)	0 (0%)
Chemotherapy	60 (62%)	9 (31%)	1 (9%)	16 (100%)	27 (100%)	7 (50%)
Targeted Therapy	22 (23%)	7 (24%)	11 (100%)	1 (6%)	1 (4%)	2 (14%)
Hormone Therapy	7 (7%)	2 (7%)	0 (0%)	5 (31%)	0 (0%)	0 (0%)
Immunotherapy	0 (0%)	-	-	-	-	-
Palliative Care	7 (7%)	0 (0%)	0 (0%)	3 (19%)	2 (7%)	2 (14%)
Bone Marrow/Stem Cell Transplant	14 (14%)	0 (0%)	0 (0%)	4 (25%)	9 (33%)	1 (7%)
No Record of Initial Treatment Reported	23 (24%)	20 (69%)	0 (0%)	0 (0%)	0 (0%)	3 (21%)

Between 2015 and 2019, there were a total of 97 analytic leukemia cancer cases, including X29 patients with CLL, 11 patients with CML, 16 patients with ALL, 27 patients with AML, and 14 patients with other leukemias. In terms of treatment methods, 1 patients (1%) received radiation therapy, 60 (62%) underwent chemotherapy, 22 (23%) received targeted therapy, 7 (7%) received hormone therapy, 7 (7%) underwent palliative care, 14 (14%) receive bone marrow or stem cell transplantation, and 23 (24%) had not record of initial treatment reported.

A line graph showing the effects of different treatments on a measured variable over time. The x-axis represents time in days, ranging from 0 to 10. The y-axis represents the measurement, from 0.0 to 1.0. Multiple lines, each with different patterns, display the data for different groups or treatments, with some lines remaining high throughout and others decreasing over time.

Five-Year Survival Rates of 97 Leukemia Patients by Stage (2015-2019)

KFSYSCC’s 2015-2019 five-year observed survival rates for 97 leukemia patients, stratified by leukemia type, are presented in the accompanying chart. As shown in the graph, the five-year survival rate is 97% for CLL, 82% for CML, 42% for ALL, 37% for AML, and 55% for other leukemias.